The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of atogepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in migraine frequency after three months of treatment
Timeframe: Baseline (T0) - 3 months of treatment with atogepant (T3)
50% Response after three months of treatment
Timeframe: Baseline (T0) - 3 months of treatment with atogepant (T3)